Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models.

David E Leahy1

  • 1Cyprotex Discovery Limited, Macclesfield, Cheshire, UK. david.leahy@dial.pipex.com

Expert Opinion on Drug Metabolism & Toxicology
|July 25, 2006
PubMed
Summary

This study introduces Cloe PK, a physiologically based model for estimating human pharmacokinetics. The model accurately predicts plasma concentrations and exposure, reducing reliance on animal testing in drug discovery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-validation pitfalls when selecting and assessing regression and classification models.

Journal of cheminformatics·2014
Same author

Automation of decision making in drug design.

Drug discovery today. Technologies·2013
Same author

Chemical Descriptors Library (CDL): a generic, open source software library for chemical informatics.

Journal of chemical information and modeling·2008
Same author

Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63.

Alternatives to laboratory animals : ATLA·2008
Same author

Competitive Workflow: novel software architecture for automating drug design.

Current opinion in drug discovery & development·2007
Same author

Prediction of in vivo tissue distribution from in vitro data. 2. Influence of albumin diffusion from tissue pieces during an in vitro incubation on estimated tissue-to-unbound plasma partition coefficients (Kpu).

Pharmaceutical research·2003

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • In Silico Drug Discovery
  • Toxicology and Risk Assessment

Background:

  • Current early drug development relies on animal data extrapolation for human pharmacokinetic (PK) estimation.
  • Physiologically based modeling offers a promising alternative for predicting human PK.
  • In vitro and in silico data integration is crucial for accurate early-stage drug assessment.

Purpose of the Study:

  • To evaluate the performance of a generic physiologically based model, Cloe PK, for estimating human plasma pharmacokinetics.
  • To compare Cloe PK's predictive accuracy against traditional in vivo animal data scaling methods.
  • To assess the utility of Cloe PK in drug discovery and risk assessment, potentially reducing animal experimentation.

Main Methods:

Related Experiment Videos

  • Application of the Cloe PK model, parameterized for human and rat physiology.
  • Estimation of plasma pharmacokinetic parameters using the Cloe PK model.
  • Comparison of model predictions with observed plasma concentration data and published scaling methods.

    • Main Results:

    • The Cloe PK model demonstrated an average divergence of 0.47 log units from observed plasma concentrations.
    • Over 70% of predicted AUC values were within threefold of observed values for the external test set.
    • Cloe PK matched or exceeded the performance of three interspecies scaling methods for clearance estimation, avoiding overprediction bias.

    Conclusions:

    • Cloe PK is a powerful and cost-effective tool for estimating drug exposure and kinetics.
    • Integrating in vitro and in silico data with Cloe PK enhances predictive accuracy in drug discovery.
    • Widespread adoption of Cloe PK can significantly reduce the necessity for animal experimentation in early drug development and risk assessment.